These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9550246)

  • 1. A syndrome of increased affect in response to risperidone among patients with schizophrenia.
    Ashleigh EA; Larsen PD
    Psychiatr Serv; 1998 Apr; 49(4):526-8. PubMed ID: 9550246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
    Sannomiya M; Katsu H; Nakayama K
    Seishin Shinkeigaku Zasshi; 2003; 105(5):643-58. PubMed ID: 12875232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
    Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
    J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
    Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
    Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone.
    Still DJ; Dorson PG; Crismon ML; Pousson C
    Psychiatr Serv; 1996 Dec; 47(12):1382-4. PubMed ID: 9117479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
    Xiang YT; Wang CY; Ungvari GS; Kreyenbuhl JA; Chiu HF; Lai KY; Lee EH; Bo QJ; Dixon LB
    Pharmacopsychiatry; 2011 Jun; 44(4):135-41. PubMed ID: 21710403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risperidone in the treatment of acute exacerbation of schizophrenia symptoms].
    Gutiérrez M; Gibert J; Bobes J; Herráiz ML; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(2):83-9. PubMed ID: 9595821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
    Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
    Kasper S; Montagnani G; Trespi G; Di Fiorino M
    Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.